Phase 3 bunionectomy and open-label safety trials of onzotrigine remain on track for initiation with topline results expected in the second half of 2027 Company plans to add oxycodone/acetaminophen (commonly known as
Todd N. Smith, a seasoned executive with deep experience commercializing pain therapies, appointed as president and chief executive officer to lead Latigo through planned late-stage development and commercialization of
Completed upsized initial public offering, including full exercise of the underwriters’ option to purchase additional shares, raising gross proceeds of $397.4 million; together with existing cash expected to fund
THOUSAND OAKS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. ("Latigo"), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today
